Fierce Pharma reported the manufacturing change on August 10, 2026. The Bloomington facility received a Form 483 in July 2025.FDA issued a warning letter in November 2025 and another Form 483 in April 2026. The site was later classified Official Action Indicated. Scholar Rock said FDA’s target decision date for apitegromab remained September 30.
Scholar Rock Removes the Bloomington Facility
Scholar Rock removed Novo Nordisk’s legacy Catalent Bloomington site from its U.S. apitegromab refiling after the facility received an Official Action Indicated inspection classification. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
An OAI Classification Changes the Filing Strategy
The regulatory history included a July 2025 Form 483, a warning letter that November, and another Form 483 following an April 2026 FDA inspection. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
Scholar Rock refiled the apitegromab application in March 2026 with two third-party fill-finish facilities, preserving manufacturing optionality while FDA reviewed the submission. This context helps readers make more focused career decisions today. This evidence supports focused pharmaceutical career decisions today.
A Second Fill-Finish Site Becomes Central
After the OAI designation, Scholar Rock shifted the U.S. application to the second facility, which the company said had recent successful FDA and EMA. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
September 30 Keeps the Timeline in Focus
The company continued to point to a September 30 FDA target decision date, showing how manufacturing-site strategy can become critical late in an approval. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
Form 483 Remediation Needs Durable Evidence
The case gives quality and regulatory teams a concrete example of why product development, CMC documentation, commercial-site readiness, and clinical progress must converge before. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
CMC Readiness Must Track Clinical Progress
A Form 483 documents inspection observations that may require corrective action. Repeated observations can increase regulatory concern when remediation does not demonstrate sustained control. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
OAI Status Raises Regulatory Consequences
Official Action Indicated is a more serious inspection classification signaling that FDA considers regulatory or administrative action indicated, making site status highly relevant to pending applications. Readers should treat this development as evidence, not a guaranteed forecast for future hiring.
To connect the OAI classification and repeated FDA findings with practical inspection readiness, read Pharmuni’s FDA Inspection Checklist for GMP Compliance in 2026. It reviews common GMP inspection areas, Form 483 observations, documentation controls, investigations, and the evidence sites should maintain before and during FDA inspections.